Antithrombotic therapy for tibial arteries balloon angioplasty

References

1. Gerhard-Herman M.D., Gornik H.L., Barrett C., Barshes N.R., Corriere M.A., Drachman D.E. et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135 (12): e726–79. DOI: 10.1161/CIR.0000000000000471
2. Criqui M.H., Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015; 116 (9): 1509–26. DOI: 10.1161/CIRCRESAHA.116.303849
3. Bommer C., Sagalova V., Heesemann E., ManneGoehlar J., Atun R., Barnighausen T. et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018; 41 (5): 963–70. DOI: 10.2337/dc17-1962
4. Farber A., Eberhardt R.T. The current state of critical limb ischemia: a systematic review. JAMA Surg. 2016; 151 (11): 1070–7. DOI: 10.1001/jamasurg.2016.2018
5. Peacock J.M., Keo H.H., Duval S., Baumgartner I., Oldenburg N.C., Jaff M.R. et al. The incidence and health economic burden of ischemic amputation in Minnesota, 2005–2008. Prev. Chronic Dis. 2011; 8 (6): A141.
6. Mustapha J.A., Katzen B.T., Neville R.F., Lookstein R.A., Zeller T., Miller L.E. et al. Determinants of long-term outcomes and costs in the management of critical limb ischemia: a population-based cohort study. J. Am. Heart Assoc. 2018; 7 (16): e009724. DOI: 10.1161/JAHA.118.009724
7. Kudo T., Chandra F.A., Ahn S.S. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J. Vasc. Surg. 2005; 41 (3): 423–35. DOI: 10.1016/j.jvs.2004.11.041
8. Agarwal S., Sud K., Shishehbor M.H. Nationwide trends of hospital admission and outcomes among critical limb ischemia patients: from 2003–2011. J. Am. Coll. Cardiol. 2016; 67 (16): 1901–13. DOI: 10.1016/j.jacc.2016.02.040
9. Rueda C.A., Nehler M.R., Perry D.J., McLafferty R.B., Casserly I.P., Hiatt W.R. et al. Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial design. J. Vasc. Surg. 2008; 47 (5): 995–9. DOI: 10.1016/j.jvs.2007.11.055
10. Baumann F., Engelberger R.P., Willenberg T., Do D.D., Kalka C., Baumgartner I. et al. Infrapopliteal lesion morphology in patients with critical limb ischemia: implications for the development of anti-restenosis technologies. J. Endovasc. Ther. 2013; 20 (2): 149–56. DOI: 10.1583/1545-1550-20.2.149
11. Jens S., Conijn A.P., Koelemay M.J., Bipat S., Reekers J.A. Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (Part 2: below the knee). Eur. J. Vasc. Endovasc. Surg. 2014; 47 (5): 536–44. DOI: 10.1016/j.ejvs.2014.02.012
12. Armstrong E.J., Bishu K., Waldo S.W. Endovascular treatment of infrapopliteal peripheral artery disease. Curr. Cardiol. Rep. 2016; 18 (4): 34. DOI: 10.1007/s11886-016-0708-y
13. Hammad T.A., Prasad A. The contemporary role of stents and angioplasty for the treatment of infrapopliteal disease in critical limb ischemia. Curr. Cardiol. Rep. 2017; 19 (7): 58. DOI: 10.1007/s11886- 017-0871-9
14. Lyden S.P. Techniques and outcomes for endovascular treatment in the tibial arteries. J. Vasc. Surg. 2009; 50 (5): 1219–23. DOI: 10.1016/j.jvs.2009.02.019
15. Nehler M.R., Duval S., Diao L., Annex B.H., Hiatt B.R., Rogers K. et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J. Vasc. Surg. 2014; 60 (3): 686.e2–95.e2. DOI: 10.1016/j.jvs.2014.03.290
16. Shishehbor M.H., Hammad T.A. Treatment of infrapopliteal disease in critical limb ischemia: beyond angioplasty. Circ. Cardiovasc. Interv. 2016; 9 (5): e003882. DOI: 10.1161/CIRCINTERVENTIONS.116.003882
17. Bhatt D.L., Peterson E.D., Harrington R.A., Ou F.S., Cannon C.P., Gibson C.M. et al. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur. Heart J. 2009; 30 (10): 1195–202. DOI: 10.1093/eurheartj/ehp099
18. Baumann F., Husmann M., Benenati J.F., Katzen B.T., Conde I.D. Bleeding risk profile in patients with symptomatic peripheral artery disease. J. Endovasc. Ther. 2016; 23 (3): 468–71. DOI: 10.1177/1526602816637621
19. Cea Soriano L., Fowkes F.G.R., Allum A.M., Johansson S., Rodriguez L.A.G. Predictors of bleeding in patients with symptomatic peripheral artery disease: a cohort study using the health improvement network in the United Kingdom. Thromb. Haemost. 2018; 118 (6): 1101–12. DOI: 10.1055/s-0038-1646923
20. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L. et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease). J. Am. Coll. Cardiol. 2006; 47 (6): 1239–312. DOI: 10.1016/j.jacc.2005.10.009
21. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G.R. Inter-society consensus for the management of peripheral arterial disease (TASC II). J. Vasc. Surg. 2007; 45 (Suppl.): S5–S67. DOI: 10.1016/j.jvs.2006.12.037
22. Hess C.N., Norgren L., Ansel G.M., Capell W.H., Fletcher J.P., Fowkes F.G.R. et al. A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (Intersociety consensus for the management of peripheral artery disease) initiative. Circulation. 2017; 135 (25): 2534–55. DOI: 10.1161/CIRCULATIONAHA.117.024469
23. Aboyans V., Ricco J.B., Bartelink M.E.L., Bjork M., Brodmann M., Cohnert T. et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur. Heart J. 2018; 39 (9): 763–816. DOI: 10.1093/eurheartj/ehx095
24. Soden P.A., Zettervall S.L., Ultee K.H., Landon B.E., O’Malley A.J., Goodney Ph.P. et al. Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. J. Vasc. Surg. 2016; 64 (6): 1633.e1–44.e1. DOI: 10.1016/j.jvs.2016.05.098 25. Beiswenger A.C., Jo A., Harth K., Kumins N.H., Shishehbor M.H., Kashyap V.S. A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease. J. Vasc. Surg. 2018; 67 (6): 1922.e6–32.e6. DOI: 10.1016/j.jvs.2018.02.047
25. Tepe G., Bantleon R., Brechtel K., Schmehl J., Zeller T., Claussen C.D. et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy – the MIRROR study: a randomised and double-blinded clinical trial. Eur. Radiol. 2012; 22 (9): 1998–2006. DOI: 10.1007/s00330-012-2441-2
26. Dotter C.T., Judkins M.P. Transluminal treatment of arteriosclerotic obstruction. Description of a new technic and a preliminary report of its application. Circulation. 1964; 30: 654–70. DOI: 10.1161/01.cir.30.5.654
27. Libow M., Gruentzig A.R., Greene L. Percutaneous transluminal coronary angioplasty. Curr. Probl. Cardiol. 1985; 10 (6): 1–55. DOI: 10.1016/0146-2806(85)90015-5
28. Pasternak R.C., Baughman K.L., Fallon J.T., Block P.C. Scanning electron microscopy after coronary transluminal angioplasty of normal canine coronary arteries. Am. J. Cardiol. 1980; 45 (3): 591–8. DOI: 10.1016/s0002-9149(80)80009-9
29. Steele P.M., Chesebro J.H., Stanson A.W., Holmes D.R., Dewanjee M.K., Badimon L. et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ. Res. 1985; 57 (1): 105–12. DOI: 10.1161/01.res.57.1.105
30. Wilentz J.R., Sanborn T.A., Haudenschild C.C., Valeri C.R., Ryan T.J., Faxon D.P. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation. 1987; 75 (3): 636–42. DOI: 10.1161/01.cir.75.3.636
31. Okura H., Shimodozono S., Hayase M., Bonneau H.N., Yock P.G., Fitzgerald P.J. Impact of deep vessel wall injury and vessel stretching on subsequent arterial remodeling after balloon angioplasty: a serial intravascular ultrasound study. Am. Heart J. 2002; 144 (2): 323–8. DOI: 10.1067/mhj.2002.122282
32. Andersen H.R., Maeng M., Thorwest M., Falk E. Remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury: insights from a porcine coronary (re)stenosis model. Circulation. 1996; 93 (9): 1716–24. DOI: 10.1161/01.cir.93.9.1716
33. Sarembock I.J., LaVeau P.J., Sigal S.L., Timms I., Sussman J., Haudenschild C. et al. Influence of inflation pressure and balloon size on the development of intimal hyperplasia after balloon angioplasty. A study in the atherosclerotic rabbit. Circulation. 1989; 80 (4): 1029–40. DOI: 10.1161/01.cir.80.4.1029
34. Guzman L.A., Mick M.J., Arnold A.M., Forudi F., Whitlow P.L. Role of intimal hyperplasia and arterial remodeling after balloon angioplasty: an experimental study in the atherosclerotic rabbit model. Arterioscler. Thromb. Vasc. Biol. 1996; 16 (3): 479–87. DOI: 10.1161/01.atv.16.3.479
35. Roubin G.S., Douglas J.S. Jr, King S.B. 3rd, Lin S.F., Hutchison N., Thomas R.G. et al. Influence of balloon size on initial success, acute complications, and restenosis after percutaneous transluminal coronary angioplasty. A prospective randomized study. Circulation. 1988; 78 (3): 557–65. DOI: 10.1161/01.cir.78.3.557
36. Bauters C., Meurice T., Hamon M., McFadden E., Lablanche J.M., Bertrand M.E. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc. Res. 1996; 31 (6): 835–46. 38. Chandrasekar B., Tanguay J.F. Platelets and restenosis. J. Am. Coll. Cardiol. 2000; 35 (3): 555–62. DOI: 10.1016/s0735-1097(99)00596-3
37. Ward M.R., Kanellakis P., Ramsey D., Jennings G.L., Bobik A. Response to balloon injury is vascular bed specific: a consequence of de novo vessel structure? Atherosclerosis. 2000; 151 (2): 407–14. DOI: 10.1016/s0021-9150(99)00407-4
38. Baumann F., Fust J., Engelberger R.P., Hugel U., Do D.D., Willenberg T. et al. Early recoil after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. J. Endovasc. Ther. 2014; 21 (1): 44–51. DOI: 10.1583/13-4486MR.1
39. Block P.C., Myler R.K., Stertzer S., Fallon J.T. Morphology after transluminal angioplasty in human beings. N. Engl. J. Med. 1981; 305 (7): 382–5. DOI: 10.1056/NEJM198108133050706 42. Essed C.E., Van den Brand M., Becker A.E. Transluminal coronary angioplasty and early restenosis. Fibrocellular occlusion after wall laceration. Br. Heart J. 1983; 49 (4): 393–6. DOI: 10.1136/hrt.49.4.393
40. Faxon D.P., Sanborn T.A., Haudenschild C.C., Ryan T.J. Effect of antiplatelet therapy on restenosis after experimental angioplasty. Am. J. Cardiol. 1984; 53 (12): 72C–6C. DOI: 10.1016/0002-9149(84)90751-3
41. Hess H., Mietaschk A., Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet. 1985; 1 (8426): 415–9. DOI: 10.1016/s0140-6736(85)91144-4
42. Heiss H.W., Just H., Middleton D., Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology. 1990; 41 (4): 263–9. DOI: 10.1177/000331979004100402
43. Ranke C., Creutzig A., Luska G., Wagner H.H., Galanski M., Bode-Boger S. et al. Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clin. Investig. 1994; 72 (9): 673–80. DOI: 10.1007/BF00212985
44. Weichert W., Meents H., Abt K., Lieb H., Hach W., Krzywanek H.J. et al. Acetylsalicylic acid – reocclusion – prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease. Vasa. 1994; 23 (1): 57–65.
45. Minar E., Ahmadi A., Koppensteiner R., Maca T., Stumpflen A., Ugurluoglu A. et al. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation. 1995; 91 (8): 2167–73. DOI: 10.1161/01.cir.91.8.2167
46. Serruys P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx. et al. A comparison of balloonexpandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 1994; 331 (8): 489–95. DOI: 10.1056/NEJM199408253310801
47. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I. et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 1994; 331 (8): 496–501. DOI: 10.1056/NEJM199408253310802
48. Topol E.J. Caveats about elective coronary stenting. N. Engl. J. Med. 1994; 331 (8): 539–41. DOI: 10.1056/NEJM199408253310811
49. Neumann F.J., Gawaz M., Ott I., May A., Mossmer G., Schomig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J. Am. Coll. Cardiol. 1996; 27 (1): 15–21. DOI: 10.1016/0735-1097(95)00433-5
50. Schomig A., Neumann F.J., Kastrati A., Schuhlen H., Blasini R., Hadamitzky M. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 1996; 334 (17): 1084–9. DOI: 10.1056/NEJM199604253341702
51. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K. et al. A clinical trial comparing three antithrombotic-drug regimens after coronaryartery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med. 1998; 339 (23): 1665–71. DOI: 10.1056/NEJM199812033392303
52. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324 (7329): 71–86. DOI: 10.1136/bmj.324.7329.71
53. Catalano M., Born G., Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J. Intern. Med. 2007; 261 (3): 276–84. DOI: 10.1111/j.1365-2796.2006.01763.x
54. Belch J., McCuish A., Campbell I., Cobbe S., Taylor R., Prescott R. et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840. DOI: 10.1136/bmj.a1840
55. Cacoub P.P., Bhatt D.L., Steg P.G., Topol E.J., Creager M.A. Patients with peripheral arterial disease in the CHARISMA trial. Eur. Heart J. 2009; 30: 192–201. DOI: 10.1093/eurheartj/ehn534
56. Hiatt W.R., Fowkes F.G., Heizer G., Berger J.S., Baumgartner I., Held P. et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. Гематология 311 Клиническая физиология кровообращения. 2021; 18 (4). DOI: 10.24022/1814-6910-2021-18-4-304-312 N. Engl. J. Med. 2017; 376: 32–40. DOI: 10.1056/NEJMoa1611688
57. Bonaca M.P., Bhatt D.L., Storey R.F., Steg P.G., Cohen M., Kuder J. et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J. Am. Coll. Cardiol. 2016; 67 (23): 2719–28. DOI: 10.1016/j.jacc.2016. 03.524
58. Wisman P.P., Teraa M., de Borst G.J., Verhaar M.C., Roest M., Moll F.L. Baseline platelet activation and reactivity in patients with critical limb ischemia. PLoS One. 2015; 10 (7): e0131356. DOI: 10.1371/journal. pone.0131356
59. Clavijo L.C., Al-Asady N., Dhillon A., Matthews R.V., Caro J., Tun H. et al. Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. Cardiovasc. Revasc. Med. 2018; 19 (5, pt A): 516–20. DOI: 10.1016/j.carrev. 2017.10.013
60. Clavijo L.C., Dhillon A., Al-Asady N., Matthews R.V., Caro J., Tun H. et al. Switch to ticagrelor in critical limb ischemia antiplatelet study (STT-CLIPS). Cardiovasc. Revasc. Med. 2018; 19 (3, pt B): 319–23. DOI: 10.1016/j.carrev.2017.08.016
61. Peeters Weem S.M., Leunissen T.C., Teraa T.C.M., Vonken E.J. Personalized antiplatelet therapy following endovascular revascularization in peripheral artery occlusive disease: a novel concept. EJVES Short Rep. 2015; 29: 11–7. DOI: 10.1016/j.ejvssr.2015.09.003
62. Subherwal S., Bach R.G., Chen A.Y., Gage B.F., Rao S.V., Newby K. et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation. 2009; 119 (14): 1873–82. DOI: 10.1161/CIRCULATIONAHA.108.828541
63. Mehran R., Pocock S.J., Nikolsky E., Clayton T., Dangas G.D., Kirtane A.J. et al. A risk score to predict bleeding in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 2010; 55 (23): 2556–66. DOI: 10.1016/j.jacc.2009.09.076
64. Costa F., van Klaveren D., James S., Heg D., Raber L., Feres F. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017; 389 (10073): 1025–34. DOI: 10.1016/S0140- 6736(17)30397-5 68. Hur D.J., Kizilgul M., Aung W.W., Roussillon K.C., Keeley E.C. Frequency of coronary artery disease in patients undergoing peripheral artery disease surgery. Am. J. Cardiol. 2012; 110 (5): 736–40. DOI: 10.1016/j.amjcard.2012.04.059
65. Nishijima A., Yamamoto N., Yoshida R., Hozawa K., Yanagibayashi S., Takikawa M. et al. Coronary artery disease in patients with critical limb ischemia undergoing major amputation or not. Plast. Reconstr. Surg. Glob. Open. 2017; 5 (6): e1377. DOI: 10.1097/GOX.0000000000001377
66. Lee M.S., Rha S.W., Han S.K., Choi B.G., Choi S.Y., Park Y. et al. Clinical outcomes of patients with critical limb ischemia who undergo routine coronary angiography and subsequent percutaneous coronary intervention. J. Invasive Cardiol. 2015; 27 (4): 213–7.
67. McFalls E.O., Ward H.B., Moritz T.E., Goldman S., Krupski W.C., Littooy F. et al. Coronary-artery revascularization before elective major vascular surgery. N. Engl. J. Med. 2004; 351: 2795–804. DOI: 10.1056/NEJMoa041905
68. Frank U., Nikol S., Belch J., Boc V., Brodmann M., Carpentier P.H. et al. ESVM guideline on peripheral arterial disease. Vasa. 2019; 48 (Suppl. 102): 1-79. DOI: 10.1024/0301-1526/a000834
69. Bonaca M.P., Gutierrez J.A., Creager M.A., Scirica B.M., Olin J., Murphy S.A. et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2°P-TIMI 50). Circulation. 2016; 133 (10): 997–1005. DOI: 10.1161/CIRCULATIONAHA.115.019355
70. Anand S.S., Caron F., Eikelboom J.W., Bosch J., Dyal L., Aboyans V. et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J. Am. Coll. Cardiol. 2018; 71 (20): 2306–15. DOI: 10.1016/j.jacc.2018.03.008

About Authors

• Daniil G. Gitel’zon, Endovascular Surgeon; ORCID
• Aleksandr G. Faybushevich, Cand. Med. Sci., Chief of Chair; ORCID
• Ekaterina A. Gitel’zon, Assistant Professor; ORCID
• Aleksandr E. Vasil’ev, Cand. Med. Sci.; ORCID
• Karen I. Danishyan, Dr. Med. Sci., Head of Department; ORCID